Ironwood Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing therapies for gastrointestinal (GI) and rare diseases. The company aims to redefine the standard of care for GI patients and reduce the burden of GI diseases. Ironwood Pharmaceuticals sells LINZESS, a prescription medication for GI conditions, and is developing apraglutide for rare gastrointestinal diseases.
- LINZESS (Linaclotide) - Serves as the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), and is approved for treating functional constipation in pediatric patients aged 6-17 years.
- Apraglutide - A next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients dependent on parenteral support, currently undergoing clinical trials and regulatory processes.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Gregory Martini Executive | Senior Vice President and Chief Financial Officer | Gregory Martini is the Senior Vice President and Chief Financial Officer of Ironwood Pharmaceuticals since January 2025. He previously served as Vice President, Strategic Finance and Investor Relations from March 2022 to January 2025 and as Senior Director, Financial Planning and Analysis from August 2020 to March 2022. | ||
John Minardo Executive | Senior Vice President, Chief Legal Officer, and Secretary | John Minardo has been serving as the Senior Vice President, Chief Legal Officer, and Secretary at Ironwood Pharmaceuticals, Inc. since August 2021. He previously held roles at Seqirus from 2015 to 2021 and at Novartis from 2007 to 2015. | ||
Michael Shetzline Executive | Senior Vice President, Chief Medical Officer, and Head of Research and Drug Development | Board member of PharmaIN Corporation | Michael Shetzline is the Senior Vice President, Chief Medical Officer, and Head of Research and Drug Development at IRWD since October 2021. He previously served as Chief Medical Officer and Head of Drug Development from January 2019 to October 2021. | |
Tammi Gaskins Executive | Senior Vice President, Chief Commercial Officer | Tammi Gaskins is the Senior Vice President, Chief Commercial Officer at Ironwood Pharmaceuticals since January 2025. Previously, she served as Vice President, Brand Management from July 2021 to January 2025 and as Senior Director, Marketing from July 2020 to July 2021. |
- Given that the full impact of your recent cost-saving initiatives is expected to materialize in Q2, can you elaborate on how you plan to manage operational performance in Q1 and what contingency measures are in place if these savings fall short?
- You indicated that R&D spending is not expected to decline in 2025 due to ongoing studies and CMC activities, so what specific milestones or cost drivers will enable a meaningful reduction in R&D expenses in 2026 without compromising critical pipeline development?
- With apraglutide's NDA submission in progress and commercial launch expenses projected to ramp up closer to 2026, how do you plan to balance the timing and magnitude of these expenses to ensure short-term margins are maintained while preparing for launch?
- In light of your comments on maintaining covenant compliance through adjustments to EBITDA, could you provide more details on the key add-backs being used and the associated risks if any of these adjustments require revision in future reporting periods?
- Considering the pricing headwinds from the Medicare Part D redesign affecting LINZESS and the focus on advancing apraglutide, how is management planning to allocate resources between sustaining LINZESS's market momentum and accelerating the commercial readiness of apraglutide, especially while striving to reduce debt?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
AMITIZA (lubiprostone) is approved by the U.S. FDA for sale in the U.S. for the treatment of IBS-C, CIC and opioid-induced constipation. Takeda also distributes the GLP-2 analog teduglutide, marketed as GATTEX® (teduglutide) in the U.S. and REVESTIVE® (teduglutide for injection) in Europe. | |
TRULANCE (plecanatide) is approved by the U.S. FDA for sale in the U.S. for the treatment of adults with IBS-C and CIC. | |
IBSRELA™ (tenapanor) is approved by the U.S. FDA for the treatment for IBS-C in adults. | |
Vibrant Gastro Inc. | Vibrant, a drug-free capsule, is approved by the U.S. FDA for the treatment of CIC in adults who have not experienced relief of their bowel symptoms by using laxative therapies at the recommended dosage for at least one month. |
Zealand is developing glepaglutide, a long-acting GLP-2 analog, for the treatment of SBS for patients who are dependent on PS and is expecting to initiate an additional Phase III clinical trial in 2025. | |
Hanmi Pharmaceutical | Hanmi Pharmaceutical is developing a GLP-2 analog, to be administered once a month, and which is in a Phase II clinical trial. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
VectivBio Holding AG | 2024 | Ironwood Pharmaceuticals acquired VectivBio Holding AG via a June 2023 tender offer for 98% of shares and a December 2023 squeeze-out merger at $17.00 per share, with a total purchase consideration of about $1.2 billion, partially financed with $400M of borrowings. The deal strategically bolsters Ironwood’s gastrointestinal portfolio by advancing apraglutide, which showed positive Phase III results for SBS-IF. |
No recent press releases or 8-K filings found for IRWD.